Replimune is saying goodbye to a further 161 employees across two Massachusetts sites as the company continues to reel from ...

Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building ...

Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia ...

But in the last three years, the company has sought to leverage its footholds in China and the U.S. to become a multinational ...

President Donald Trump has ordered the FDA to perform priority reviews of psychedelic drugs as part of a push to clear ...

Novo Nordisk is gearing up to submit its rare blood disorder drug to the FDA after the former Forma Therapeutics asset ...

Roche is handing over $595 million to bolster its Foundation Medicine business with a deal to snap up SAGA Diagnostics. | ...

In another sign that the biotech IPO market is heating back up, Odyssey Therapeutics has made a fresh announcement of its ...

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win this year, offering ...

A phase 2 trial combining Agenus’ and MiNK Therapeutics’ cancer candidates has missed its primary endpoint. But with the ...

Biomarkers are redefining how oncology trials are designed, shifting from single-mutation targeting to comprehensive genomic ...

| Bioprocessing is evolving rapidly in a shifting landscape of innovative and complex products, processes and technologies.